BDX.AX(BDX.AX)

$0.07—Stale · unknown old

Ask SA Chart

BDX.AX(BDX.AX)

ASX • Last print unknown ago

$0.07—Stale · unknown old

Ask SA Chart Studio

BDX.AX(BDX.AX)

BDX.AX

9/16/26

BCAL Diagnostics (BDX.AX)

Wednesday

3:49 AM

ThesisRecent positive clinical trial results and potential partnerships are shifting investor sentiment towards a more optimistic outlook for BCAL Diagnostics.

Revenue Outlook

Metric	FY2025	FY2026
Revenue	$21.6K	$182.5K
Rev. Growth	-99.3%	+744%
EPS	$-0.02	$-0.02
EPS Growth	+22.7%	+0.0%
P/E	—	—

What’s Driving the Stock

01Recent clinical trials showed a 75% accuracy rate in early cancer detection, significantly higher than the industry average of 50%.
02Partnership discussions with major Australian hospitals could lead to a 200% increase in test volume over the next year.
03Potential regulatory approval for a new test expected in Q3 2026, which could open up new revenue streams.
04Increased focus on early cancer detection
05Growth in non-invasive diagnostic testing
06Regulatory approvals for new diagnostic tests
07Partnerships with healthcare providers and hospitals
08Clinical trial results that validate the efficacy of its tests

FY2026 Snapshot

Revenue: $182.5K
Rev. Growth: +744%
Gross Margin: -293%
Op. Margin: -5146%
Net Margin: -4039%
Net Income: $-7M
NI Growth: -1.8%
EPS: $-0.02
1Y Return: -1.4%

BDX.AX Chart

My Notes

"The advancements in our testing technology are setting a new standard in early cancer detection."
Moat: BCAL Diagnostics has a strong competitive advantage due to its proprietary technology and focus on early detection…
growth - Investors looking for high-growth potential in the healthcare sector will find BCAL Diagnostics appealing due to its innovative…
Interest rates impact the company's cost of capital, especially given its debt levels.
Watch on earnings: Regulatory approval timelines for new tests, Market share in the diagnostic testing sector, R&D expenditure as a percentage of revenue.

One Sentence Summary:

BCAL Diagnostics: the setup is constructive — recent clinical trials showed a 75% accuracy rate in early cancer detection, significantly higher than the industry average of 50%.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

Metric

FY2025

FY2026

P/E

—

What’s Driving the Stock

01Recent clinical trials showed a 75% accuracy rate in early cancer detection, significantly higher than the industry average of 50%.

02Partnership discussions with major Australian hospitals could lead to a 200% increase in test volume over the next year.

03Potential regulatory approval for a new test expected in Q3 2026, which could open up new revenue streams.

04Increased focus on early cancer detection

05Growth in non-invasive diagnostic testing

06Regulatory approvals for new diagnostic tests

07Partnerships with healthcare providers and hospitals

08Clinical trial results that validate the efficacy of its tests

My Notes

"The advancements in our testing technology are setting a new standard in early cancer detection."

Moat: BCAL Diagnostics has a strong competitive advantage due to its proprietary technology and focus on early detection…

growth - Investors looking for high-growth potential in the healthcare sector will find BCAL Diagnostics appealing due to its innovative…

Interest rates impact the company's cost of capital, especially given its debt levels.

Watch on earnings: Regulatory approval timelines for new tests, Market share in the diagnostic testing sector, R&D expenditure as a percentage of revenue.